Triple Antihypertensive Pill May Lower Incidence of Recurrent Stroke

Follow Drugslib on

By Elana Gotkine HealthDay Reporter

Medically reviewed by Drugs.com

via HealthDay

FRIDAY, April 24, 2026 -- For patients with intracerebral hemorrhage, treatment with a once-daily pill containing three low-dose antihypertensive agents is associated with a lower incidence of recurrent stroke, according to a study published in the April 23 issue of the New England Journal of Medicine.

Craig S. Anderson, M.B., B.S., Ph.D., from the George Institute for Global Health at the University of New South Wales in Sydney, and colleagues conducted a double-blind, randomized, placebo-controlled trial involving patients (mean age, 58 years) with a history of intracerebral hemorrhage who had a systolic blood pressure of 130 to 160 mmHg at baseline. After a two-week run-in phase, during which all patients received a once-daily pill containing telmisartan at 20 mg, amlodipine at 2.5 mg, and indapamide at 1.25 mg (the triple pill), patients were randomly assigned to continue receiving the triple pill or matching placebo (833 and 837 participants, respectively).

The researchers found that recurrent stroke had occurred in 4.6 and 7.4 percent of patients in the triple-pill and placebo groups, respectively, at a median follow-up of 2.5 years (hazard ratio, 0.61). During follow-up, the mean systolic blood pressure was 127 and 138 mmHg, respectively. The triple-pill group had a lower incidence of major cardiovascular events compared with the placebo group (6.6 versus 9.8 percent). Serious adverse events occurred in 23.2 and 26.0 percent of patients in the triple-pill and placebo groups, respectively; early discontinuation of the trial regimen due to an adverse event occurred in 13.6 and 6.0 percent, respectively.

"These study results have the potential to mark a real shift in how we manage blood pressure following a stroke," Anderson said in a statement. "This single-pill triple combination helped patients reach target blood pressure levels."

Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2026-04-25 01:43

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords